The effect of the APOE genotype on individual BrainAGE in normal aging, Mild cognitive impairment, and Alzheimer's Disease

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Löwe, Luise Christine ^a   Gaser, Christian ^b   Franke, Katja ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

ACCURACY; AGED; AGING; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; ARTICLE; BRAIN AGE GAP ESTIMATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; SCORING SYSTEM; BRAIN; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; GENETICS; LONGITUDINAL STUDY; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; COGNITIVE DYSFUNCTION; FEMALE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS;

EID: 84978736575     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157514     Document Type: Article

References (87)

1. Hinrichs C, Singh V, Mukherjee L, Xu G, Chung MK, Johnson SC. Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset. NeuroImage. 2009; 48(1):138-49. Epub 2009/ 06/02. doi: 10.1016/j.neuroimage.2009.05.056 PMID: 19481161; PubMed Central PMCID: PMC2773131.
2. Bigler ED, Lowry CM, Anderson CV, Johnson SC, Terry J, Steed M. Dementia, quantitative neuroimaging, and apolipoprotein E genotype. AJNR American journal of neuroradiology. 2000; 21(10):1857-68. Epub 2000/12/08. PMID: 11110538.
3. Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr., et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol. 2010; 31(2):347-54. Epub 2010/01/16. ajnr.A1809 [pii] doi: 10.3174/ajnr.A1809 PMID: 20075088.
4. Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiology of aging. 2011; 32(12):2322 e19-27. Epub 2010/07/03. doi: 10.1016/j.neurobiolaging.2010.05.023 PMID: 20594615; PubMed Central PMCID: PMC2951483.
5. Jack CR Jr., Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain: a journal of neurology. 2010; 133(11):3336-48. Epub 2010/ 10/12. doi: 10.1093/brain/awq277 PMID: 20935035; PubMed Central PMCID: PMC2965425.
6. Kester MI, Scheltens P. Dementia: the bare essentials. Pract Neurol. 2009; 9(4):241-51. doi: 10.1136/ jnnp.2009.182477 PMID: 19608778.
7. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. doi: 10.1016/j.jalz.2011.03.008 PMID: 21514249; PubMed Central PMCID: PMCPMC3312027.
8. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of internal medicine. 2004; 256 (3):183-94. Epub 2004/08/25. doi: 10.1111/j.1365-2796.2004.01388.x PMID: 15324362.
9. Davatzikos C, Xu F, An Y, Fan Y, Resnick SM. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain. 2009; 132(Pt 8):2026-35. Epub 2009/05/ 07. awp091 [pii] doi: 10.1093/brain/awp091 PMID: 19416949.
10. Jack CR Jr., Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004; 62 (4):591-600. Epub 2004/02/26. PMID: 14981176; PubMed Central PMCID: PMC2730165.
11. Spulber G, Niskanen E, MacDonald S, Smilovici O, Chen K, Reiman EM, et al. Whole brain atrophy rate predicts progression from MCI to Alzheimer's disease. Neurobiology of aging. 2010; 31(9):1601-5. Epub 2008/10/03. doi: 10.1016/j.neurobiolaging.2008.08.018 PMID: 18829136.
12. Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. NeuroImage. 2004; 23(2):708-16. Epub 2004/10/19. doi: 10.1016/j.neuroimage.2004.07.006 PMID: 15488420.
13. Fotenos AF, Snyder AZ, Girton LE, Morris JC, Buckner RL. Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology. 2005; 64(6):1032-9. Epub 2005/03/23. doi: 10.1212/01.WNL.0000154530.72969.11 PMID: 15781822.
14. Anderson VM, Schott JM, Bartlett JW, Leung KK, Miller DH, Fox NC. Gray matter atrophy rate as a marker of disease progression in AD. Neurobiology of aging. 2012; 33(7):1194-202. Epub 2010/12/18. doi: 10.1016/j.neurobiolaging.2010.11.001 PMID: 21163551.
15. Franke K, Ziegler G, Klöppel S, Gaser C, the Alzheimer's Disease Neuroimaging Initiative. Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: Exploring the influence of various parameters. NeuroImage. 2010; 50(3):883-92. Epub 2010/01/15. S1053-8119(10)00010-8 [pii] doi: 10.1016/j.neuroimage.2010.01.005 PMID: 20070949.
16. Gaser C, Franke K, Kloppel S, Koutsouleris N, Sauer H. in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer's Disease. PloS one. 2013; 8(6):e67346. Epub 2013/07/05. doi: 10.1371/ journal.pone.0067346 PMID: 23826273; PubMed Central PMCID: PMC3695013.
17. Franke K, Gaser C. Longitudinal Changes in Individual BrainAGE in Healthy Aging, Mild Cognitive Impairment, and Alzheimer's Disease. GeroPsych. 2012; 25(4):235-45. doi: 10.1024/1662-9647/ a000074
18. Driscoll I, Davatzikos C, An Y, Wu X, Shen D, Kraut M, et al. Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology. 2009; 72(22):1906-13. Epub 2009/06/ 03. 72/22/1906 [pii] doi: 10.1212/WNL.0b013e3181a82634 PMID: 19487648.
19. Sluimer JD, van der Flier WM, Karas GB, van Schijndel R, Barnes J, Boyes RG, et al. Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. European radiology. 2009; 19(12):2826-33. Epub 2009/07/21. doi: 10.1007/s00330-009-1512-5 PMID: 19618189; PubMed Central PMCID: PMC2778773.
20. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(5):1977-81. Epub 1993/03/01. PMID: 8446617; PubMed Central PMCID: PMC46003.
21. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature genetics. 1994; 7 (2):180-4. Epub 1994/06/01. doi: 10.1038/ng0694-180 PMID: 7920638.
22. Nalbantoglu J, Gilfix BM, Bertrand P, Robitaille Y, Gauthier S, Rosenblatt DS, et al. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Annals of neurology. 1994; 36(6):889-95. Epub 1994/12/01. doi: 10.1002/ana. 410360614 PMID: 7998776.
23. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010; 68 (2):270-81. Epub 2010/10/20. doi: 10.1016/j.neuron.2010.10.013 PMID: 20955934.
24. Bertram L, Tanzi RE. The current status of Alzheimer's disease genetics: what do we tell the patients? Pharmacological research: the official journal of the Italian Pharmacological Society. 2004; 50(4):385-96. Epub 2004/08/12. doi: 10.1016/j.phrs.2003.11.018 PMID: 15304236.
25. Saunders AM. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. Journal of neuropathology and experimental neurology. 2000; 59(9):751-8. Epub 2000/09/27. PMID: 11005255.
26. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261(5123):921-3. Epub 1993/08/13. PMID: 8346443.
27. Brouwers N, Sleegers K, Van Broeckhoven C. Molecular genetics of Alzheimer's disease: an update. Annals of medicine. 2008; 40(8):562-83. Epub 2008/07/09. doi: 10.1080/07853890802186905 PMID: 18608129.
28. Deuschl G, Maier W. S3- Leitlinie Demenzen.: Deutsche Gesellschaft fp ° r Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft fp ° r Neurologie (DGN); 2009.
29. Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Archives of neurology. 2005; 62 (3):454-9. Epub 2005/03/16. doi: 10.1001/archneur.62.3.454 PMID: 15767511.
30. Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology. 2005; 65(12):1888-93. Epub 2005/12/29. doi: 10. 1212/01.wnl.0000188871.74093.12 PMID: 16380608.
31. Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M, et al. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology. 2008; 70(19 Pt 2):1842-9. Epub 2008/04/11. 01.wnl.0000304038.37421.cc [pii] doi: 10.1212/01.wnl.0000304038.37421.cc PMID: 18401023.
32. Jack CR Jr., Petersen RC, Xu YC, O'Brien PC, Waring SC, Tangalos EG, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Annals of neurology. 1998; 43(3):303-10. Epub 1998/03/20. doi: 10.1002/ana.410430307 PMID: 9506546; PubMed Central PMCID: PMC2752747.
33. Liddell MB, Lovestone S, Owen MJ. Genetic risk of Alzheimer's disease: advising relatives. The British journal of psychiatry: the journal of mental science. 2001; 178(1):7-11. Epub 2001/01/03. PMID: 11136203.
34. Roses AD, Strittmatter WJ, Pericak-Vance MA, Corder EH, Saunders AM, Schmechel DE. Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet. 1994; 343(8912):1564-5. Epub 1994/06/18. PMID: 7911881.
35. Kurz A, Altland K, Lautenschlager N, Zimmer R, Busch R, Gerundt I, et al. Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups. Journal of neurology. 1996; 243(6):452-6. Epub 1996/06/01. PMID: 8803817.
36. Honea RA, Vidoni E, Harsha A, Burns JM. Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. Journal of Alzheimer's disease: JAD. 2009; 18(3):553-64. Epub 2009/07/09. doi: 10.3233/JAD-2009-1163 PMID: 19584447; PubMed Central PMCID: PMC2892293.
37. Hua X, Lee S, Yanovsky I, Leow AD, Chou YY, Ho AJ, et al. Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. NeuroImage. 2009; 48(4):668-81. Epub 2009/07/21. doi: 10.1016/j.neuroimage. 2009.07.011 PMID: 19615450; PubMed Central PMCID: PMC2971697.
38. Lehtovirta M, Soininen H, Laakso MP, Partanen K, Helisalmi S, Mannermaa A, et al. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. Journal of neurology, neurosurgery, and psychiatry. 1996; 60(6):644-9. Epub 1996/06/01. PMID: 8648331; PubMed Central PMCID: PMC1073948.
39. Mori E, Lee K, Yasuda M, Hashimoto M, Kazui H, Hirono N, et al. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Annals of neurology. 2002; 51(2):209-14. Epub 2002/02/09. PMID: 11835377.
40. Manning EN, Barnes J, Cash DM, Bartlett JW, Leung KK, Ourselin S, et al. APOE epsilon4 is associated with disproportionate progressive hippocampal atrophy in AD. PloS one. 2014; 9(5):e97608. Epub 2014/06/01. doi: 10.1371/journal.pone.0097608 PMID: 24878738; PubMed Central PMCID: PMC4039513.
41. Basso M, Gelernter J, Yang J, MacAvoy MG, Varma P, Bronen RA, et al. Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiology of aging. 2006; 27 (10):1416-24. Epub 2005/09/27. doi: 10.1016/j.neurobiolaging.2005.08.002 PMID: 16182410.
42. Querbes O, Aubry F, Pariente J, Lotterie JA, Demonet JF, Duret V, et al. Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain. 2009; 132(Pt 8):2036-47. Epub 2009/05/15. awp105 [pii] doi: 10.1093/brain/awp105 PMID: 19439419.
43. Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, et al. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology. 1996; 47(1):190-6. Epub 1996/07/01. PMID: 8710076.
44. Mortimer JA, Snowdon DA, Markesbery WR. The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology. Alzheimer disease and associated disorders. 2009; 23(2):152-7. Epub 2009/06/03. PMID: 19484916; PubMed Central PMCID: PMC2752689.
45. Berlau DJ, Corrada MM, Head E, Kawas CH. APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology. 2009; 72(9):829-34. Epub 2009/03/04. doi: 10.1212/01.wnl.0000343853.00346.a4 PMID: 19255410; PubMed Central PMCID: PMC2667799.
46. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular psychiatry. 2011; 16(9):903-7. Epub 2011/05/11. doi: 10.1038/mp.2011.52 PMID: 21556001; PubMed Central PMCID: PMC3162068.
47. Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacology bulletin. 1988; 24(4):627-8. Epub 1988/01/01. PMID: 3249763.
48. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993; 43(11):2412-4. Epub 1993/11/01. PMID: 8232972.
49. Cockrell JR, Folstein MF. Mini-Mental State Examination (MMSE). Psychopharmacology bulletin. 1988; 24(4):689-92. Epub 1988/01/01. PMID: 3249771.
50. Ashburner J, Friston KJ. Unified segmentation. NeuroImage. 2005; 26(3):839-51. Epub 2005/06/16. S1053-8119(05)00110-2 [pii] doi: 10.1016/j.neuroimage.2005.02.018 PMID: 15955494.
51. Tohka J, Zijdenbos A, Evans A. Fast and robust parameter estimation for statistical partial volume models in brain MRI. NeuroImage. 2004; 23(1):84-97. Epub 2004/08/25. doi: 10.1016/j.neuroimage.2004. 05.007 S1053811904002745 [pii]. PMID: 15325355.
52. Rajapakse JC, Giedd JN, Rapoport JL. Statistical approach to segmentation of single-channel cerebral MR images. IEEE Transactions on Medical Imaging. 1997; 16(2):176-86. Epub 1997/04/01. doi: 10. 1109/42.563663 PMID: 9101327.
53. Cuadra MB, Cammoun L, Butz T, Cuisenaire O, Thiran JP. Comparison and validation of tissue modelization and statistical classification methods in T1-weighted MR brain images. IEEE Transactions on Medical Imaging. 2005; 24(12):1548-65. Epub 2005/12/15. doi: 10.1109/TMI.2005.857652 PMID: 16350916.
54. Tipping ME. The Relevance Vector Machine. In: Solla SA, Leen TK, Müller K-R, editors. Advances in Neural Information Processing Systems 12. Cambridge, MA: MIT Press; 2000. p. 652-8.
55. Franke K, Gaser C, for the Alzheimer's Disease Neuroimaging Initiative. Longitudinal changes in individual BrainAGE in healthy aging, mild cognitive impairment, and Alzheimer's disease. GeroPsych: The Journal of Gerontopsychology and Geriatric Psychiatry. 2012; 25(4):235-45.
56. Schölkopf B, Smola A. Learning with Kernels: Support vector machines, regularization, optimization, and beyond. Cambridge: MA: MIT; 2002.
57. Aguilar C, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, et al. Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. Frontiers in aging neuroscience. 2014; 6:145. Epub 2014/07/30. doi: 10.3389/fnagi.2014.00145 PMID: 25071554; PubMed Central PMCID: PMC4094911.
58. Anderson VM, Schott JM, Bartlett JW, Leung KK, Miller DH, Fox NC. Gray matter atrophy rate as a marker of disease progression in AD. Neurobiology of Aging. 2012; 33(7):1194-202. Epub 2010/12/18. S0197-4580(10)00475-6 [pii] doi: 10.1016/j.neurobiolaging.2010.11.001 PMID: 21163551.
59. Jack CR Jr., Weigand SD, Shiung MM, Przybelski SA, O'Brien PC, Gunter JL, et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology. 2008; 70(19):1740-52. Epub 2007/11/23. 01.wnl.0000281688.77598.35 [pii] doi: 10.1212/01.wnl.0000281688.77598.35 PMID: 18032747.
60. Desikan RS, Fischl B, Cabral HJ, Kemper TL, Guttmann CR, Blacker D, et al. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD. Neurology. 2008; 71(11):819-25. Epub 2008/08/02. 01.wnl.0000320055.57329.34 [pii] doi: 10.1212/01.wnl.0000320055.57329.34 PMID: 18672473.
61. Sluimer JD, van der Flier WM, Karas GB, van Schijndel R, Barnes J, Boyes RG, et al. Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. European Radiology. 2009; 19(12):2826-33. Epub 2009/07/21. doi: 10.1007/s00330-009-1512-5 PMID: 19618189.
62. Dukart J, Schroeter ML, Mueller K. Age correction in dementia-matching to a healthy brain. PLoS One. 2011; 6(7):e22193. Epub 2011/08/11. doi: 10.1371/journal.pone.0022193 PONE-D-11-03484 [pii]. PMID: 21829449.
63. Jones DT, Machulda MM, Vemuri P, McDade EM, Zeng G, Senjem ML, et al. Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology. 2011; 77(16):1524-31. Epub 2011/10/07. WNL.0b013e318233b33d [pii] doi: 10.1212/WNL.0b013e318233b33d PMID: 21975202.
64. Yu L, Boyle P, Schneider JA, Segawa E, Wilson RS, Leurgans S, et al. APOE epsilon4, Alzheimer's disease pathology, cerebrovascular disease, and cognitive change over the years prior to death. Psychol Aging. 2013; 28(4):1015-23. doi: 10.1037/a0031642 PMID: 23647000; PubMed Central PMCID: PMCPMC3766432.
65. Wilson RS, Leurgans SE, Boyle PA, Bennett DA. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Archives of Neurology. 2011; 68(3):351-6. Epub 2011/03/16. 68/3/351 [pii] doi: 10.1001/archneurol.2011.31 PMID: 21403020.
66. Hirono N, Hashimoto M, Yasuda M, Kazui H, Mori E. Accelerated memory decline in Alzheimer's disease with apolipoprotein epsilon4 allele. The Journal of neuropsychiatry and clinical neurosciences. 2003; 15(3):354-8. Epub 2003/08/21. PMID: 12928512.
67. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC Jr., Rimmler JB, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology. 1995; 45(7):1323-8. Epub 1995/07/01. PMID: 7617191.
68. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology. 1996; 47(2):444-8. Epub 1996/ 08/01. PMID: 8757018.
69. Holmes C, Levy R, McLoughlin DM, Powell JF, Lovestone S. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry. 1996; 61(6):580-3. Epub 1996/12/01. PMID: 8971103; PubMed Central PMCID: PMC486650.
70. Stern Y, Brandt J, Albert M, Jacobs DM, Liu X, Bell K, et al. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Annals of neurology. 1997; 41 (5):615-20. Epub 1997/05/01. doi: 10.1002/ana.410410510 PMID: 9153523.
71. Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr., et al. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease. NeuroImage Clinical. 2014; 4:461-72. Epub 2014/03/19. doi: 10.1016/j.nicl.2013.12.012 PMID: 24634832; PubMed Central PMCID: PMC3952354.
72. Franko E, Joly O. Evaluating Alzheimer's disease progression using rate of regional hippocampal atrophy. PloS one. 2013; 8(8):e71354. Epub 2013/08/21. doi: 10.1371/journal.pone.0071354 PMID: 23951142; PubMed Central PMCID: PMC3741167.
73. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2011; 7(3):280-92. Epub 2011/04/26. doi: 10.1016/j.jalz.2011. 03.003 PMID: 21514248; PubMed Central PMCID: PMC3220946.
74. Alzheimer'sAssociationWorkingGroup. Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group. Lancet. 1996; 347(9008):1091-5. Epub 1996/04/20. PMID: 8602063.
75. Tsuang D, Larson EB, Bowen J, McCormick W, Teri L, Nochlin D, et al. The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series. Archives of neurology. 1999; 56(12):1489-95. Epub 1999/12/11. PMID: 10593304.
76. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. The New England journal of medicine. 1998; 338(8):506-11. Epub 1998/02/19. doi: 10.1056/NEJM199802193380804 PMID: 9468467.
77. Boissonneault GA. MCI and dementia: diagnosis and treatment. JAAPA: official journal of the American Academy of Physician Assistants. 2010; 23(1):18, 21-2. Epub 2010/02/09. PMID: 20135920.
78. Susanto TA, Pua EP, Zhou J. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e. Journal of Alzheimer's disease: JAD. 2015; 45(1):253-68. Epub 2014/12/20. doi: 10.3233/JAD-142451 PMID: 25524955.
79. Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. American journal of human genetics. 1981; 33(1):11-24. Epub 1981/01/01. PMID: 7468588; PubMed Central PMCID: PMC1684875.
80. Thakkinstian A, Bowe S, McEvoy M, Smith W, Attia J. Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis. American journal of epidemiology. 2006; 164(9):813-22. Epub 2006/08/19. doi: 10.1093/aje/kwj279 PMID: 16916985.
81. Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the apolipoprotein E system in man. American journal of human genetics. 1980; 32(3):339-47. Epub 1980/05/01. PMID: 7386461; PubMed Central PMCID: PMC1686062.
82. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Archives of neurology. 2006; 63 (5):674-81. Epub 2006/05/10. doi: 10.1001/archneur.63.5.674 PMID: 16682537.
83. Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, et al. APOE genotype predicts when-not whether-one is predisposed to develop Alzheimer disease. Nature genetics. 1998; 19(4):321-2. Epub 1998/08/11. doi: 10.1038/1206 PMID: 9697689.
84. Sobel E, Louhija J, Sulkava R, Davanipour Z, Kontula K, Miettinen H, et al. Lack of association of apolipoprotein E allele epsilon 4 with late-onset Alzheimer's disease among Finnish centenarians. Neurology. 1995; 45(5):903-7. Epub 1995/05/01. PMID: 7746404.
85. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. Journal of the International Neuropsychological Society: JINS. 2002; 8(3):448-60. Epub 2002/04/10. PMID: 11939702.
86. Stern Y, Zarahn E, Hilton HJ, Flynn J, DeLaPaz R, Rakitin B. Exploring the neural basis of cognitive reserve. Journal of clinical and experimental neuropsychology. 2003; 25(5):691-701. Epub 2003/06/ 20. doi: 10.1076/jcen.25.5.691.14573 PMID: 12815506.
87. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of internal medicine. 2004; 256(3):240-6. Epub 2004/08/25. doi: 10.1111/j. 1365-2796.2004.01380.x PMID: 15324367.